Practice guidelines for the diagnosis and management of skin and soft-tissue infections

Clinical Infectious Diseases

Volumn 41, Issue 10, 2005, Pages 1373-1406

  Stevens, Dennis L ^a,c   Bisno, Alan L ^e   Chambers, Henry F ^f,g   Everett, E Dale ^l   Dellinger, Patchen ^b   Goldstein, Ellie J C ^h,i   Gorbach, Sherwood L ^m   Hirschmann, Jan V ^c,d   Kaplan, Edward L ^n,o   Montoya, Jose G ^j,k   Wade, James C ^p  

^a Boise VA Medical Center   (United States)

^b Department of Surgery ^*  (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h R M ALDEN RESEARCH LABORATORY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k PALO ALTO MEDICAL FOUNDATION   (United States)

^l UNIVERSITY OF MISSOURI   (United States)

^m TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^o UNIVERSITY OF MINNESOTA   (United States)

^p MEDICAL COLLEGE OF WISCONSIN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BICARBONATE; C REACTIVE PROTEIN; CARBAPENEM; CEFALEXIN; CEFOXITIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; CREATINE KINASE; CREATININE; DAPTOMYCIN; DICLOXACILLIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; METICILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULTAMICILLIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ACANTHAMOEBA; AEROMONAS HYDROPHILA; ANTHRAX; ANTIBIOTIC RESISTANCE; ASPERGILLUS; BACILLUS ANTHRACIS; BACTEROIDES TECTUM; BALAMUTHIA; BIOLOGICAL WARFARE; BITE; BLOOD CELL COUNT; BLOOD CULTURE; CANDIDA ALBICANS; CAPNOCYTOPHAGA; CARBUNCLE; CAT SCRATCH DISEASE; CELLULITIS; CLOSTRIDIUM HISTOLYTICUM; CLOSTRIDIUM NOVYI; CLOSTRIDIUM PERFRINGENS; CLOSTRIDIUM SEPTICUM; CRYPTOCOCCUS; CYTOMEGALOVIRUS; DISEASE SEVERITY; DRUG SENSITIVITY; EIKENELLA CORRODENS; ERYSIPELAS; FOURNIER GANGRENE; FRANCISELLA TULARENSIS; FUSARIUM; FUSOBACTERIUM; GAS GANGRENE; GRAM STAINING; HEMANGIOMATOSIS; HERPES SIMPLEX VIRUS; HORSE DISEASE; HUMAN; IATROGENIC DISEASE; IMMUNE DEFICIENCY; IMPETIGO; INFECTION SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUCOR; MYOSITIS; NECROTIZING FASCIITIS; NEEDLE BIOPSY; NEUTROPENIA; PASTEURELLA; PEPTOSTREPTOCOCCUS; PLAGUE; PORPHYROMONAS; PRACTICE GUIDELINE; PREVOTELLA; PRIORITY JOURNAL; PUNCH BIOPSY; REVIEW; RHIZOPUS; SARCOPTES SCABIEI; SKIN ABSCESS; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PYOGENES; STRONGYLOIDES STERCORALIS; SURGICAL INFECTION; SYMPTOM; TRICHOSPORON BEIGELII; TULAREMIA; VARICELLA ZOSTER VIRUS; VIBRIO VULNIFICUS; YERSINIA PESTIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; CATS; DOGS; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; WOUND INFECTION; ZOONOSES;

EID: 27744448866     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/497143     Document Type: Review

References (236)

1. Wong CH, Khin LW, Heng KS, Tan KC, Low CO. The LRINEC (Laboratory risk indicator for necrotizing fasciitis) score: a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Grit Care Med 2004; 32:1535-41.
2. Thorell E, Jackson MA, Bratcher D, Swanson DS, Selvaragan R. Antimicrobial resistance of Staphylococcus aureus from Kansas City children: what is the appropriate current therapy for pediatric staphylococcal infections [abstract 252]? In: Proceedings and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: Infectious Diseases Society of America, 2004:81.
3. Ruhe JJ, Monson TP. Use of tetracyclines for infections caused by methicillin-resistant Staphylococcus aureus [abstract 516]. In: Proceedings and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: Infectious Diseases Society of America, 2004:139.
4. Van Beneden CA, Facklam R, Lynfield R, Glennen A, Beall B, Whitney C. Erythromycin resistance among invasive group A streptococcal infections, United States, 1999-2001 [abstract 345]. In: Proceedings and abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America (Boston). Alexandria, VA: Infectious Diseases Society of America, 2004:102.
5. Yun HJ, Lee SW, Yoon GM, et al. Prevalence and mechanisms of low-and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 2003; 51:619-23.
6. Committee on Infectious Diseases, American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Pickering LK, ed. Red book 2003 report of the Committee on Infectious Diseases. 26th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2003:693-4.
7. Miller LG, Perdreau-Remington F, Rieg G, et al. Necrotizing fasciitis caused by community-associated methicillin-resistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005; 352:1445-53.
8. Ferrieri P, Dajani AS, Wannamaker LW, Chapman SS. Natural history of impetigo. 1. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. J Clin Invest 1972; 51:2851-62.
9. Adams BB. Dermatologic disorders of the athlete. Sports Med 2002; 32:309-21.
10. Fehrs LJ, Flanagan K, Kline S, Facklam RR, Quackenbush K, Foster LR. Group A beta-hemolytic streptococcal skin infections in a US meat-packing plant. JAMA 1987; 258:3131-4.
11. Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis 2002; 22:42-51.
12. Darmstadt GL, Lane AT. Impetigo: an overview. Pediatr Dermatol 1994; 11:293-303.
13. Demidovich CW, Wittier RR, Ruff ME, Bass JW, Browning WC. Impetigo: current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 1990; 144:1313-5.
14. Kaplan EL, Anthony BF, Chapman SS, Ayoub EM, Wannamaker LW. The influence of the site of infection on the immune response to group A streptococci. J Clin Invest 1970; 49:1405-14.
15. Bisno AL, Nelson KE, Waytz P, Brunt J. Factors influencing serum antibody response in streptococcal pyoderma. J Lab Clin Med 1973; 81:410-20.
16. Kaplan EL, Wannamaker LW. Suppression of the anti-streptolysin O response by cholesterol and by lipid extracts of rabbit skin. J Exp Med 1976; 144:754-67.
17. Derrick CW Jr, Dillon HC Jr. Impetigo contagiosa. Am Fam Physician 1971; 4:75-81.
18. Ferrieri P, Dajani AS, Wannamaker LW. A controlled study of penicillin prophylaxis against streptococcal impetigo. J Infect Dis 1974; 129:429-38.
19. Dagan R, Bar-David Y. Comparison of amoxicillin and davulanic acid (augmentin) for the treatment of nonbullous impetigo. Am J Dis Child 1989; 143:916-8.
20. Barton LL, Friedman AD. Impetigo: a reassessment of etiology and therapy. Pediatr Dermatol 1987; 4:185-8.
21. Barton LL, Friedman AD, Sharkey AM, Schneller DJ, Swierkosz EM. Impetigo contagiosa III: comparative efficacy of oral erythromycin and topical mupirocin. Pediatr Dermatol 1989; 6:134-8.
22. Britton IW, Fajardo JE, Krafte-Jacobs B. Comparison of mupirocin and erythromycin in the treatment of impetigo. J Pediatr 1990; 117:827-9.
23. Weinstein L, Le Frock J. Does antimicrobial therapy of streptococcal pharyngitis or pyoderma alter the risk of glomerulonephritis? J Infect Dis 1971; 124:229-31.
24. Meislin HW, Lerner SA, Graves MH, et al. Cutaneous abscesses: anaerobic and aerobic bacteriology and outpatient management. Ann Intern Med 1977; 87:145-9.
25. Ghoneim AT, McGoldrick J, Blick PW, Flowers MW, Marsden AK, Wilson DH. Aerobic and anaerobic bacteriology of subcutaneous abscesses. Br J Surg 1981; 68:498-500.
26. Brook I, Frazier EH. Aerobic and anaerobic bacteriology of wounds and cutaneous abscesses. Arch Surg 1990; 125:1445-51.
27. Leach RD, Eykyn SJ, Phillips I, Corrin B, Taylor EA. Anaerobic axillary abscess. Br Med J 1979; 2:5-7.
28. Whitehead SM, Leach RD, Eykyn SJ, Phillips I. The aetiology of scrotal sepsis. Br J Surg 1982; 69:729-30.
29. Edmiston CE Jr, Walker AP, Krepel CJ, Gohr C. The nonpuerperal breast infection: aerobic and anaerobic microbial recovery from acute and chronic disease. J Infect Dis 1990; 162:695-9.
30. Whitehead SM, Leach RD, Eykyn SJ, Phillips I. The aetiology of perirectal sepsis. Br J Surg 1982; 69:166-8.
31. Diven DG, Dozier SE, Meyer DJ, Smith EB. Bacteriology of inflamed and uninflamed epidermal inclusion cysts. Arch Dermatol 1998; 134:49-51.
32. Llera JL, Levy RC. Treatment of cutaneous abscess: a double-blind clinical study. Ann Emerg Med 1985; 14:15-9.
33. Macfie J, Harvey J. The treatment of acute superficial abscesses: a prospective clinical trial. Br J Surg 1977; 64:264-6.
34. Decker MD, Lybarger JA, Vaughn WK, Hutcheson RH Jr, Schaffner W. An outbreak of staphylococcal skin infections among river rafting guides. Am J Epidemiol 1986; 124:969-76.
35. Sosin DM, Gunn RA, Ford WL, Skaggs JW. An outbreak of furunculosis among high school athletes. Am J Sports Med 1989; 17:828-32.
36. Zimakoff J, Rosdahl VT, Petersen W, Scheibel J. Recurrent staphylococcal furunculosis in families. Scand J Infect Dis 1988; 20:403-5.
37. Hedstrom SA. Recurrent staphylococcal furunculosis: bacteriological findings and epidemiology in 100 cases. Scand J Infect Dis 1981; 13:115-9.
38. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996; 156:1109-12.
39. Lipsky BA, Pecoraro RE, Ahroni JH, Peugeot RL. Immediate and long-term efficacy of systemic antibiotics for eradicating nasal colonization with Staphyloccus aureus. Eur J Clin Microbiol Infect Dis 1992; 11:43-7.
40. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA 1988; 260:2682-5.
41. Bisno AL, Stevens DL. Streptococcal infections in skin and soft tissues. N Engl J Med 1996; 334:240-5.
42. Chartier C, Grosshans E. Erysipelas. Int J Dermatol 1990; 29:459-67.
43. Chartier C, Grosshans E. Erysipelas: an update. Int J Dermatol 1996; 35:779-81.
44. Swartz MN. Clinical practice: cellulitis. N Engl J Med 2004; 350:904-12.
45. Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol 1992; 127:155-9.
46. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346:1200-6.
47. York MK, Gibbs L, Perdreau-Remington F, Brooks GF. Characterization of antimicrobial resistance in Streptococcus pyogenes isolates from the San Francisco Bay area of northern California. J Clin Microbiol 1999; 37:1727-31.
48. Dupuy A, Benchikhi H, Roujeau JC, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ 1999; 318:1591-4.
49. Dan M, Heller K, Shapira I, Vidne B, Shibolet S. Incidence of erysipelas following venectomy for coronary artery bypass surgery. Infection 1987; 15:107-8.
50. Baddour LM, Bisno AL. Recurrent cellulitis after saphenous venectomy for coronary bypass surgery. Ann Intern Med 1982; 97:493-6.
51. Simon MS, Cody RL. Cellulitis after axillary lymph node dissection for carcinoma of the breast. Am J Med 1992; 93:543-8.
52. Baddour LM. Breast cellulitis complicating breast conservation therapy. J Intern Med 1999; 245:5-9.
53. Bouma J, Dankert J. Recurrent acute leg cellulitis in patients after radical vulvectomy. Gynecol Oncol 1988; 29:50-7.
54. Dankert J, Bouma J. Recurrent acute leg cellulitis after hysterectomy with pelvic lymphadenectomy. Br J Obstet Gynaecol 1987; 94:788-90.
55. Perl B, Gottehrer NP, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999; 29:1483-8.
56. Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med 1988; 148:2451-2.
57. Hook EW III, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986; 146:295-7.
58. Sachs MK. The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990; 150:1907-12.
59. Leppard BJ, Seal DV, Colman G, Hallas G. The value of bacteriology and serology in the diagnosis of cellulitis and erysipelas. Br J Dermatol 1985; 112:559-67.
60. Sigurdsson AF, Gudmundsson S. The etiology of bacterial cellulitis as determined by fine-needle aspiration. Scand J Infect Dis 1989; 21:537-42.
61. Newell PM, Norden CW. Value of needle aspiration in bacteriologic diagnosis of cellulitis in adults. J Clin Microbiol 1988; 26:401-4.
62. Lebre C, Girard-Pipau F, Roujeau JC, Revuz J, Saiag P, Chosidow O. Value of fine-needle aspiration in infectious cellulitis. Arch Dermatol 1996; 132:842-3.
63. Lutomski DM, Trott AT, Runyon JM, Miyagawa CI, Staneck JL, Rivera JO. Microbiology of adult cellulitis. J Fam Pract 1988; 26:45-8.
64. Duvanel T, Auckenthaler R, Rohner P, Harms M, Saurat JH. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med 1989; 149:293-6.
65. Eriksson B, Jorup-Ronstrom C, Karkkonen K, Sjoblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis 1996; 23:1091-8.
66. Bernard P, Toty L, Mounier M, Denis F, Bonnetblanc JM. Early detection of streptococcal group antigens in skin samples by latex particle agglutination. Arch Dermatol 1987; 123:468-70.
67. Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM. Streptococcal cause of erysipelas and cellulitis in adults: a microbiologic study using a direct immunofluorescence technique. Arch Dermatol 1989; 125:779-82.
68. Baddour LM, Bisno AL. Recurrent cellulitis after coronary bypass surgery. Association with superficial fungal infection in saphenous venectomy limbs. JAMA 1984; 251:1049-52.
69. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. Clin Infect Dis 1996; 23:1162-4.
70. Eriksson BK. Anal colonization of group G β-hemolytic streptococci in relapsing erysipelas of the lower extremity. Clin Infect Dis 1999; 29:1319-20.
71. Burman WJ, Cohn DL, Reves RR, Wilson ML. Multifocal cellulitis and monoarticular arthritis as manifestations of Helicobacter cinaedi bacteremia. Clin Infect Dis 1995; 20:564-70.
72. Kirsner RS, Pardes JB, Eaglstein WH, Falanga V. The clinical spectrum of lipodermatosclerosis. J Am Acad Dermatol 1993; 28:623-7.
73. Jorup-Ronstrom C, Britton S, Gavlevik A, Gunnarsson K, Redman AC. The course, costs, and complications of oral versus intravenous penicillin therapy of erysipelas. Infection 1984; 12:390-4.
74. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med 2004; 164:1669-74.
75. Bergkvist PI, Sjobeck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis 1997; 29:377-82.
76. Bergkvist PI, Sjobeck K. Relapse of erysipelas following treatment with prednisolone or placebo in addition to antibiotics: a 1-year follow-up. Scand J Infect Dis 1998; 30:206-7.
77. Babb RR, Spittell JA Jr, Martin WJ, Schirger A. Prophylaxis of recurrent lymphangitis complicating lymphedema. JAMA 1966; 195:871-3.
78. Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect 1991; 22:37-40.
79. Sjoblom AC, Eriksson B, Jorup-Ronstrom C, Karkkonen K, Lindqvist M. Antibiotic prophylaxis in recurrent erysipelas. Infection 1993; 21:390-3.
80. Wang JH, Liu YC, Cheng DL, et al. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis 1997; 25:685-9.
81. Kasseroller R. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema. Anticancer Res 1998; 18:2227-30.
82. Groom AV, Wolsey DH, Naimi TS, et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001; 286:1201-5.
83. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998; 279:593-8.
84. Centers for Disease Control and Prevention. Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections-Los Angeles County, California, 2002-2003. MMWR Morb Mortal Wkly Rep 2003; 52:88.
85. Ma XX, Ito T, Tiensasitorn C, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46:1147-52.
86. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40:4289-94.
87. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin- resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35:819-24.
88. Methicillin-resistant Staphylococcus aureus infections in correctional facilities-Georgia, California, and Texas, 2001-2003. MMWR Morb Mortal Wkly Rep 2003; 52:992-6.
89. Methicillin-resistant Staphylococcus aureus infections among competitive sports participants-Colorado, Indiana, Pennsylvania, and Los Angeles County, 2000-2003. MMWR Morb Mortal Wkly Rep 2003; 52:793-5.
90. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44:3408-13.
91. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Linezolid MRSA Study Group. Clin Infect Dis 2002; 34:1481-90.
92. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390-8.
93. Ahrenholz DH. Necrotizing soft-tissue infections. Surg Clin North Am 1988; 68:199-214.
94. Lewis RT. Necrotizing soft-tissue infections. Infect Dis Clin North Am 1992; 6:693-703.
95. Rea WJ, Wyrick WJ Jr. Necrotizing fasciitis. Ann Surg 1970; 172:957-64.
96. Giuliano A, Lewis F Jr, Hadley K, Blaisdell FW. Bacteriology of necrotizing fasciitis. Am J Surg 1977; 134:52-7.
97. Stevens DL, Tanner MH, Winship J, et al. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. N Engl J Med 1989; 321:1-7.
98. Chelsom J, Halstensen A, Haga T, Hoiby EA. Necrotising fasciitis due to group A streptococci in western Norway: incidence and clinical features. Lancet 1994; 344:1111-5.
99. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J 1999; 18:1096-100.
100. Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J 2003; 96:968-73.
101. Stevens DL. Dilemmas in the treatment of invasive Streptococcus pyogenes infections. Clin Infect Dis 2003; 37:341-3.
102. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999; 28:800-7.
103. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37:333-40.
104. Sissolak D, Weir WR. Tropical pyomyositis. J Infect 1994; 29:121-7.
105. Laucks SS. Fournier's gangrene. Surg Clin North Am 1994; 74:1339-52.
106. Eke N. Fournier's gangrene: a review of 1726 cases. Br J Surg 2000; 87:718-28.
107. Altemeier WA, Fullen WD. Prevention and treatment of gas gangrene. JAMA 1971; 217:806-13.
108. Stevens DL, Laine BM, Mitten JE. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother 1987; 1:312-6.
109. Stevens DL, Maier KA, Laine BM, Mitten JE. Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis 1987; 155:220-8.
110. Stevens DL, Bryant AE, Adams K, Mader JT. Evaluation of hyperbaric oxygen therapy for treatment of experimental Clostridium perfringens infection. Clin Infect Dis 1993; 17:231-7.
111. Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJ. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999; 340:85-92.
112. Goldstein EJ, Citron DM, Wield B, et al. Bacteriology of human and animal bite wounds. J Clin Microbiol 1978; 8:667-72.
113. Goldstein EJ. New horizons in the bacteriology, antimicrobial susceptibility and therapy of animal bite wounds. J Med Microbiol 1998; 47:95-7.
114. Goldstein EJ, Reinhardt JF, Murray PM, Finegold SM. Outpatient therapy of bite wounds: demographic data, bacteriology, and a prospective, randomized trial of amoxicillin/clavulanic acid versus penicillin +/- dicloxacillin. Int J Dermatol 1987; 26:123-7.
115. Talan DA, Abrahamian FM, Moran GJ, Citron DM, Tan JO, Goldstein EJ. Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. Clin Infect Dis 2003; 37:1481-9.
116. Transmission of HIV by human bite. Lancet 1987; 2:522.
117. Vidmar L, Poljak M, Tomazic J, Seme K, Klavs I. Transmission of HIV-1 by human bite. Lancet 1996; 347:1762.
118. Dusheiko GM, Smith M, Scheuer PJ. Hepatitis C virus transmitted by human bite. Lancet 1990; 336:503-4.
119. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet 1989; 1:889-93.
120. Fiumara NJ, Exner JH. Primary syphilis following a human bite. Sex Transm Dis 1981; 8:21-2.
121. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 1999; 281:1735-45.
122. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999; 341:815-26.
123. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50:909-19.
124. Bass JW, Freitas BC, Freitas AD, et al. Prospective randomized double blind placebo-controlled evaluation of azithromycin for treatment of cat-scratch disease. Pediatr Infect Dis J 1998; 17:447-52.
125. Reboli AC, Farrar WE. Erysipelothrix rhusiopathiae: an occupational pathogen. Clin Microbiol Rev 1989; 2:354-9.
126. Venditti M, Gelfusa V, Tarasi A, Brandimarte C, Serra P. Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae. Antimicrob Agents Chemother 1990; 34:2038-40.
127. Srinivasan A, Kraus CN, DeShazer D, et al. Glanders in a military research microbiologist. N Engl J Med 2001; 345:256-8.
128. Perry RD, Fetherston JD. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 1997; 10:35-66.
129. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000; 283:2281-90.
130. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994; 19:42-7.
131. Johansson A, Berglund L, Gothefors L, Sjostedt A, Tarnvik A. Ciprofloxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000; 19:449-53.
132. Chocarro A, Gonzalez A, Garcia I. Treatment of tularemia with ciprofloxacin. Clin Infect Dis 2000; 31:623.
133. Perez-Castrillon JL, Bachiller-Luque P, Martin-Luquero M, Mena-Martin FJ, Herreros V. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clin Infect Dis 2001; 33:573-6.
134. Brennan TA, Leape LL, Laird NM, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice study I. N Engl J Med 1991; 324:370-6.
135. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999: Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999; 20:250-78.
136. Gaynes RP, Culver DH, Horan TC, Edwards JR, Richards C, Tolson JS. Surgical site infection (SSI) rates in the United States, 1992-1998: the National Nosocomial Infections Surveillance System basic SSI risk index. Clin Infect Dis 2001; 33(Suppl 2):S69-S77.
137. Dellinger EP. Approach to the patient with postoperative fever. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious diseases in medicine and surgery. Philadelphia: W. B. Saunders, 1998:903-9.
138. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery 1961; 50:161-8.
139. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326:281-6.
140. Stone HH, Haney BB, Kolb LD, Geheber CE, Hooper CA. Prophylactic and preventive antibiotic therapy: timing, duration and economics. Ann Surg 1979; 189:691-9.
141. Dellinger EP, Gross PA, Barrett TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. Infectious Diseases Society of America. Clin Infect Dis 1994; 18:422-7.
142. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 2004; 38:1706-15.
143. McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose antimicrobial prophylaxis for major surgery: a systematic review. Aust N Z J Surg 1998; 68:388-96.
144. Bartlett P, Reingold AL, Graham DR, et al. Toxic shock syndrome associated with surgical wound infections. JAMA 1982; 247:1448-50.
145. Raab MG, O'Brien M, Hayes JM, Graham DR. Postoperative toxic shock syndrome. Am J Orthop 1995; 24:130-6.
146. Huizinga WK, Kritzinger NA, Bhamjee A. The value of adjuvant systemic antibiotic therapy in localised wound infections among hospital patients: a comparative study. J Infect 1986; 13:11-6.
147. Mandell GL, Bennett JE, Dolin R. Mandell, Douglas and Bennett's principles and practice of infectious diseases. New York: Churchill Livingstone, 1995.
148. Howard RJ. Surgical infectious diseases. Norwalk: Appleton & Lange, 1988.
149. Fry DE. Surgical infections. Boston: Little, Brown and Company, 1995.
150. Greenfield LJ, Mulholland MW, Oldham KT, Zelenock GB. Surgery: scientific principles and practice. Philadelphia: J. B. Lippincott Company, 1993.
151. Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL, Sabiston S. Textbook of surgery: the biologic basis of modern surgical practice. Philadelphia: W. B. Saunders and Company, 2001.
152. Wilmore DW, Cheung LY, Harken AH, Holcroft JW, Meakins JL, Soper NJ. ACS surgery: principles and practice. New York: WebMD, 2002.
153. Gorbach SL, Bartlett JG, Blacklow NR. Infectious diseases. Philadelphia: W. B. Saunders and Company, 1998.
154. Dellinger EP. Nosocomial infection. In: Wilmore DW, Cheung LY, Harken AH, Holcroft JW, Meakins JL, Soper NJ, eds. ACS surgery: principles and practice. New York: WebMD, 2002:1221-38.
155. Cruse PJE. Wound infections: epidemiology and clinical characteristics. In: Howard RJ, Simmons RL, eds. Surgical infectious diseases. Norwalk: Appleton & Lange, 1988:319-29.
156. Bobrow BJ, Pollack CV Jr, Gamble S, Seligson RA. Incision and drainage of cutaneous abscesses is not associated with bacteremia in afebrile adults. Ann Emerg Med 1997; 29:404-8.
157. Meislin HW. Pathogen identification of abscesses and cellulitis. Ann Emerg Med 1986; 15:329-32.
158. Dellinger EP. Postoperative wound infection. In: Schlossberg D, ed. Current therapy of infectious disease. St. Louis: Mosby, 1996:337-9.
159. Wade JC. Management of infection in patients with acute leukemia. Hematol Oncol Clin North Am 1993; 7:293-315.
160. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993:328:1323-32.
161. Donowitz GR. Fever in the compromised host. Infect Dis Clin North Am 1996; 10:129-48.
162. Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infections in immunocompromised patients. Medicine (Baltimore) 1985; 64:115-33.
163. Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infection in the compromised host. Annu Rev Med 1983; 34:205-17.
164. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730-51.
165. NCCN practice guidelines for fever and neutropenia. National Comprehensive Cancer Network. Oncology (Williston Park) 1999; 13:197-257.
166. Lopez FA, Sanders CV. Dermatologic infections in the immunocompromised (non-HIV) host. Infect Dis Clin North Am 2001; 15:671-702, xi.
167. Wingard JR, Santos GW, Saral R. Differences between first and subsequent fevers during prolonged neutropenia. Cancer 1987; 59:844-9.
168. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501-9.
169. Glauser M. Empiric therapy of bacterial infections in patients with severe neutropenia. Diagn Microbiol Infect Dis 1998; 31:467-72.
170. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992; 14:1201-7.
171. European Organization for Research and Treatment of Cancer (EORTC)
172. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-9.
173. Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia: mortality and hospital stay. Ann Intern Med 1989; 110:9-16.
174. Wenzel RP. Perspective: attributable mortality-the promise of better antimicrobial therapy. J Infect Dis 1998; 178:917-9.
175. Brown AE, Kiehn TE, Armstrong D. Bacterial resistance in the patient with neoplastic disease. Infect Dis Clin Pract 1995; 4(Suppl 3): S136-44.
176. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
177. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18:3558-85.
178. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37:382-9.
179. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72:101-11.
180. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86:668-72.
181. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351:1391-402.
182. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
183. Goodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164:731-40.
184. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:662-78.
185. Wingard JR, Merz WG, Saral R. Candida tropicalis: a major pathogen in immunocompromised patients. Ann Intern Med 1979; 91:539-43.
186. Jarowski CI, Fialk MA, Murray HW, et al. Fever, rash, and muscle tenderness: a distinctive clinical presentation of disseminated candidiasis. Arch Intern Med 1978; 138:544-6.
187. Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 1986; 65:268-79.
188. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250-60.
189. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
190. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32:358-66.
191. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillemia in patients with cancer: a 10-year study. Clin Infect Dis 2000; 31:188-9.
192. Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987; 317:1105-8.
193. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive Aspergillus infections in a pediatric hospital: a ten-year review. Pediatr Infect Dis J 1993; 12:673-82.
194. Gartenberg G, Bottone EJ, Keusch GT, Weitzman I. Hospital-acquired mucormycosis (Rhizopus rhizopodiformis) of skin and subcutaneous tissue: epidemiology, mycology and treatment. N Engl J Med 1978; 299:1115-8.
195. Dennis JE, Rhodes KH, Cooney DR, Roberts GD. Nosocomical Rhizopus infection (zygomycosis) in children. J Pediatr 1980; 96:824-8.
196. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infect Dis 1992; 14(Suppl 1):S43-53.
197. Kremery V Jr, Jesenska Z, Spanik S, et al. Fungaemia due to Fusarium spp. in cancer patients. J Hosp Infect 1997; 36:223-8.
198. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999-1008.
199. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12:40-79.
200. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175:1459-66.
201. Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis 1999; 28:1071-9.
202. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:696-709.
203. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36:1445-57.
204. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29:1402-7.
205. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
206. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340:764-71.
207. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
208. Cagnoni PJ, Walsh TJ, Prendergast MM, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18:2476-83.
209. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181:309-16.
210. Ichiki Y, Hirose M, Akiyama T, Esaki C, Kitajima Y. Skin infection caused by Mycobacterium avium. Br J Dermatol 1997; 136:260-3.
211. Sanderson TL, Moskowitz L, Hensley GT, Cleary TJ, Penneys N. Disseminated Mycobacterium avium-intracellulare infection appearing as a panniculitis. Arch Pathol Lab Med 1982; 106:112-4.
212. Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405-12.
213. Bennett C, Vardiman J, Golomb H. Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 1986; 80:891-6.
214. Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19:263-73.
215. Gaviria JM, Garcia PJ, Garrido SM, Corey L, Boeckh M. Nontuberculous mycobacterial infections in hematopoietic stem cell transplant recipients: characteristics of respiratory and catheter-related infections. Biol Blood Marrow Transplant 2000; 6:361-9.
216. Berkey P, Bodey GP. Nocardial infection in patients with neoplastic disease. Rev Infect Dis 1989; 11:407-12.
217. Simpson GL, Stinson EB, Egger MJ, Remington JS. Nocardial infections in the immunocompromised host: a detailed study in a denned population. Rev Infect Dis 1981; 3:492-507.
218. Smego RA Jr, Moeller MB, Gallis HA. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med 1983; 143:711-8.
219. Dimino-Emme L, Gurevitch AW. Cutaneous manifestations of disseminated cryptococcosis. J Am Acad Dermatol 1995; 32:844-50.
220. Neuville S, Dromer F, Morin O, Dupont B, Ronin O, Lortholary O. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003; 36:337-47.
221. Anderson DJ, Schmidt C, Goodman J, Pomeroy C. Cryptococcal disease presenting as cellulitis. Clin Infect Dis 1992; 14:666-72.
222. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710-8.
223. Shuttleworth D, Philpot CM, Knight AG. Cutaneous cryptococcosis: treatment with oral fluconazole. Br J Dermatol 1989; 120:683-7.
224. Davies SF, Sarosi GA, Peterson PK, et al. Disseminated histoplasmosis in renal transplant recipients. Am J Surg 1979; 137:686-91.
225. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:688-95.
226. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152:1172-81.
227. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 1980; 65:869-78:
228. Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308:1448-53.
229. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980; 142:338-46.
230. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123:89-96.
231. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. J Infect Dis 1996; 174:470-5.
232. Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321:7-12.
233. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997; 337:1105-11.
234. Balfour HH Jr, Benson C, Braun J, et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994; 7:254-60.
235. Toome BK, Bowers KE, Scott GA. Diagnosis of cutaneous cytomegalovirus infection: a review and report of a case. J Am Acad Dermatol 1991; 24:860-7.
236. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32:1249-72.